Toxin-antigen conjugates as selection tools for antibody producing cells

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Antibody generation requires extensive and expensive screening.
• Hybridoma technology is crucial for monoclonal antibody production.
• Current methods for antibody specificity screening are inefficient.

Purpose of the Study:

• To develop a novel method for selecting hybridoma cells based on antibody specificity.
• To eliminate the need for traditional, time-consuming antibody screening procedures.
• To utilize antigen-toxin conjugates for direct selection of antibody-producing hybridomas.

Main Methods:

• Development and characterization of methotrexate (toxin) and methotrexate-fluorescein (antigen-toxin) conjugate.
• Assessment of conjugate toxicity.
• Determination of antibody (B13-DE1) effect on conjugate toxicity.
• Evaluation of hybridoma cell growth in the presence of antigen-toxin conjugates.

Main Results:

• Methotrexate and the methotrexate-fluorescein conjugate exhibited dose-dependent toxicity.
• The fluorescein-specific antibody B13-DE1 modulated the toxicity of the conjugate.
• Hybridoma cells producing fluorescein-specific antibodies demonstrated growth in the presence of fluorescein-toxin conjugates.

Conclusions:

• Antigen-toxin conjugates offer a viable method for selecting hybridoma cells based on antibody specificity.
• This novel approach significantly reduces the cost and time associated with antibody screening.
• The findings pave the way for more efficient monoclonal antibody generation.